Skip to Main Content

Research demonstrating the remarkable cancer-killing power of genetically rewired white blood cells — known as CAR-T therapy — has long grabbed the spotlight at the annual meeting of the American Society of Hematology.

This year, though, the debate is no longer about whether or not CAR-T kills cancer. New research to be presented at the conference, kicking off Saturday in Atlanta, will focus instead on the long-term durability of CAR-T, the potential to target different types of blood cancers, and the feasibility of treating large numbers of patients scattered across the globe.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.